Medingo has had many discussions with payers in the U.S. and has received very favorable feedback about their willingness to cover and contract for the SOLO system under their current insulin pump policies as long as the system is priced competitively.

Roche has tremendous expertise in working with payers to gain reimbursement for new diabetes products and technologies and has a large government and private insurance contracting organization worldwide. We will utilize this strength to gain coverage for the SOLO system.  Since our plan is to be competitive with other insulin pump options that are currently covered, we feel confident in gaining widespread reimbursement.

Check this area for updates on insurance reimbursement.